СПИСОК ИСПОЛЬЗОВАННЫХ ИСТОЧНИКОВ

Поставить закладку

Андреевская С.Н., Смирнова Т.Г., Черноусова Л.Н. Туберкулез органов дыхания / Руководство для врачей под ред. проф. А.Э. Эргешова, глава 1.1 «Возбудитель туберкулеза, строение, генетика, физиология, лекарственная устойчивость, нетуберкулезные микобактерии». – М.: ООО «Галлея-Принт», 2017. – с. 10-33. ISBN 978-5-9907563-7-3
Богородская Е.М., Кудлай Д.А., Литвинов В.И. Проблемы лекарственной устойчивости микобактерий / Под ред. Е.М. Богородской, Д.А. Кудлая, В.И. Литвинова // М.: МНПЦБТ. – 2021. – 504 с.
Борисов С.Е., Иванушкина Т.Н., Иванова Д.А., Филиппов А.В., Литвинова Н.В., Родина О.В., Гармаш Ю.Ю., Сафонова С.Г., Богородская Е.М. Эффективность и безопасность включающих бедаквилин шестимесячных режимов химиотерапии у больных туберкулезом органов дыхания // Туберкулез и социально-значимые заболевания. – 2015. – № 3. – С. 30-49.
Борисов С.Е., Филиппов А.В., Иванова Д.А., Иванушкина Т.Н., Литвинова Н.В., Гармаш Ю.Ю. Эффективность и безопасность основанных на использовании бедаквилина режимов химиотерапии у больных туберкулезом органов дыхания: непосредственные и окончательные результаты // Туберкулез и болезни легких. – 2019. – Т. 97. – № 5. – С. 28-42.
Литвинов В.И., Макарова М.В., Краснова М.А. Нетуберкулёзные микобактерии. – М.: МНПЦБТ. – 2008. – 256 с.
Литвинов В.И., Мороз А.М. Лабораторные исследования при туберкулезе. – М.: МНПЦБТ – 2013. – 343 с. Литвинов В.И., Богородская Е.М., Борисов С.Е. Нетуберкулезные микобактерии, микобактериозы / Под ред. В.И. Литвинова, Е.М. Богородской, С.Е. Борисова // М.: МНПЦБТ. – 2014. – 256 с.
Оттен Т.Ф., Васильев А.В. Микобактериоз. - СПб: Медицинская пресса, 2005. – 224 с.
Устинова В.В., Смирнова Т.Г., Андреевская С.Н., Андриевская И.Ю., Ларионова Е.Е., Черноусова Л.Н. Секвенирование геномов шести клинических штаммов нетуберкулезных микобактерий // Туберкулёз и болезни лёгких. – 2018. – Т. 96. – № 12. – с. 70-71 DOI 10.21292/2075-1230-2018-96-12-70-71.
Устинова В.В., Смирнова Т.Г., Варламов Д.А., Ларионова Е.Е., Андреевская С.Н., Киселева Е.А., Андриевская И.Ю., Черноусова Л.Н. Полногеномное секвенирование клинического штамма Mycobacterium gordonae / В сборнике: «Молекулярная диагностика 2017» (сб. тр. IХ Всероссийской научно-практической конференции с международным участием). – 2017. – Т. 2. – с. 28-31.
Устинова В.В., Смирнова Т.Г., Варламов Д.А.,Ларионова Е.Е., Андриевская И.Ю., Черноусова Л.Н. Полногеномное секвенирование генома Mycobacterium heckeshornense // Бактериология. – 2017. - Т. 2. – №3. – с. 108-109.
Перетокина И.В., Крылова Л.Ю., Михайлова Ю.Д., Свириденко М.А., Хахалина А.А., Сафонова С.Г. Изучение взаимосвязи значений минимальных ингибирующих концентраций бедаквилина в отношении Mycobacterium tuberculosis, выделенных от впервые выявленных больных, с наличием чувствительности/устойчивости к ПТП и их принадлежностью к генетическим семействам // Туберкулез и социально-значимые заболевания. – 2021. – № 4. – с. 17-26.
Смирнова Т.Г., Андреевская С.Н., Ларионова Е.Е., Черноусова Л.Н., Устинова В.В. Two-step algorithm for MTB/NTMB differentiating using new tests based on real-time PCR / 52nd Union World Conference on Lung Health AS-WCLH-2021-00312.
Смирнова Т.Г. Новые молекулярно-генетические методы для видовой идентификации нетуберкулезных микобактерий в диагностическом материале // Вестник ЦНИИТ. – 2020. – №2. – с. 94-96 DOI: 10.7868/S2587667820060394
Adjemian J., Daniel-Wayman S., Ricotta E., Prevots D.R. Epidemiology of Nontuberculous Mycobacteriosis // Semin Respir Crit Care Med. – 2018. – Vol. 39. – №3. – р. 325-335. doi: 10.1055/s-0038-1651491.
Alcaide F., Calatayud L., Santín M., Martín R. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansassii // Antimicrob. Agents. Chemother. – 2004. – Vol. 48. – №12. – р. 4562-5.
Alexander D.C., Vasireddy R., Vasireddy S et al. Emergence of mmpT5 variants during bedaquiline treatment of Mycobacterium intracellulare lung disease // J Clin Microbiol. – 2017. – Vol. 55. - №2. – р. 574-584. doi: 10.1128/JCM.02087-16.
Almeida D., Ioerger T.., Tyagi S. et al. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis // Antimicrob Agents Chemother. – 2016. – Vol. 60. – р. 4590–4599. doi: 10.1128/AAC.00753-16.
Andries K., Verhasselt P., Guillemont J., Göhlmann H., Neefs J. et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis // Science. – 2005. – Vol. 307. – № 5707. – р. 223-7. doi: 10.1126/science.1106753.
Andries K., Villellas C., Coeck N. et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline // PLoS One. – 2014. – № 9: e102135. doi: 10.1371/journal.pone.0102135.
Babady N.E., Hall L., Abbenyi A.T., еt al. Evaluation of Mycobacterium avium complex clarithromycin susceptibility testing using SLOMYCO Sensititre panels and JustOne strips // J Clin Microbiol. – 2010. – Vol. 48. – №5. – р. 1749-52.
Bakuła Z., Kościuch J., Safianowska A., Proboszcz M., Bielecki J., van Ingen J. et al. Clinical, radiological and molecular features of Mycobacterium kansasii pulmonary disease // Respir Med. – 2018. – Vol. 139. – p. 91-100. doi: 10.1016/ j.rmed.2018.05.007.
Brown-Elliott B., Nash K., Wallace R. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria // Clin Microbiol Rev. – 2012. – Vol. 25. – N 3. – p. 545-82. doi: 10.1128/CMR. 05030-11.
Brown-Elliott B., Philley J., Griffith D., Thakkar F., Wallace R. In vitro susceptibility testing of bedaquiline against Mycobacterium avium complex // Antimicrob Agents Chemother. – 2017. – Vol. 61. – N 2. – e01798-16. doi: 10.1128/AAC.01798-16.
Brown-Elliott B., Wallace R. In vitro susceptibility testing of bedaquiline against Mycobacterium abscessus complex // Antimicrob Agents Chemother. – 2019. – Vol. 63. – N 2:e01919-18. doi: 10.1128/AAC.01919-18.
Brown-Elliott B.A., Woods G.L. antimycobacterial susceptibility testing of nontuberculous Mycobacteria // J Clin Microbiol. – 2019. – Vol. 57. – N. 10 :e00834-19. doi: 10.1128/JCM.00834-19.
Cavusoglu C., Soyler I., Akinci P. Activities of Linezolid against nontuberculous mycobacteria // New Microbiol. – 2007. – Vol. 30. – N 4. – p. 411-4.
CLSI. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard – second edition: document M24-A2. CLSI, Wayne, PA, USA, 2011.
CLSI. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes (3rd ed.), CLSI, Wayne, PA, USA, 2018.
Cowman S., van Ingen J., Griffith D.E., Loebinger M.R. Non-tuberculous mycobacterial pulmonary disease // Eur Respir J. – 2019. – Vol. 54. – N. 1:1900250. doi: 10.1183/13993003.00250-2019.
Dahl V.N., Mølhave M., Fløe A. et al. Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review // Int J Infect Dis. – 2022. – Vol. 125. – p. 120-131. doi: 10.1016/j.ijid.2022.10.013.
Daley C.L. Mycobacterium avium complex disease // Microbiol Spectr. – 2017. – Vol. 5. – N2. doi: 10.1128/microbiolspec.TNMI7-0045-2017.
Daley C., Iaccarino J., Lange C., Cambau E., Wallace R. Andrejak C. et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline // Eur Respir J. – 2020. – Vol. 56. – N. 1:2000535. doi: 10.1183/13993003.00535-2020.
DeStefano M., Shoen C., Cynamon M. Therapy for Mycobacterium kansasii Infection: Beyond 2018 // Front Microbiol. – 2018. – Vol. 9. – p. 2271. doi: 10.3389/fmicb.2018.02271.
Diacon A., Pym A., Grobusch M., de los Rios J., Gotuzzo E., Vasilyeva I. et al. TMC207-C208 Study Group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline // N Engl J Med. – 2014. – Vol. 371. – N. 8. – p. 723-32. doi: 10.1056/NEJMoa1313865.
European Committee on Antimicrobial Susceptibility Testing. EUCAST subcommittee on MIC distributions and epidemiological cut-off values (ECOFFs). 2014. – URL: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_ files/Consultation/2017/MIC_and_ECOFF/EUCAST_MIC_and_ECOFF_ discussion_ document _version_3_20170309.pdf.
Falkinham J.O. Nontuberculous mycobacteria in the environment // Clin Chest Med. – 2002. – Vol.23. – N.3. – p. 529-51. doi: 10.1016/s0272-5231(02)00014-x
Falkinham J.O. Ecology of Nontuberculous Mycobacteria // Microorganisms. – 2021. – Vol. 309. – N.11. – p. 2262. doi: 10.3390/microorganisms9112262.
Flume P.A., Griffith D.E., Chalmers J.D., et al. development of drugs for nontuberculous mycobacterial disease: clinicians' interpretation of a US Food and Drug Administration Workshop // Chest. – 2021. – Vol. 159. – N. 2. – p. 537-543. doi: 10.1016/j.chest.2020.08.2055.
Griffith D., Aksamit T., Brown-Elliott B., Catanzaro A., Daley C., Gordin F. et al. ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases // Am J Respir Crit Care Med. – 2007. – Vol. 175. – N 4. – p. 367-416. doi: 10.1164/rccm. 200604-571ST.
Halstrom S., Price P., Thomson R. Review: Environmental mycobacteria as a cause of human infection // Int J Mycobacteriol. – 2015. – Vol. 4. – N 2. – p. 81-91. doi: 10.1016/j.ijmyco.2015.03.002.
Hards K., Robson J., Berney M., Shaw L., Bald D., Koul A. et al. Bactericidal mode of action of bedaquiline // J Antimicrob Chemother. – 2015. – Vol. 70. – N.7 – p. 2028-37. doi: 10.1093/jac/dkv054.
Heifets L. Drug susceptibility in the chemotherapy of mycobacterial infections // Boca Raton Ann Arbor Boston London: CRC Press; 2000.
Heifets L. Mycobacterial infections caused by nontuberculous mycobacteria //Am. J. Respir. Crit. Care Med. – 2004. – Vol. 25. – №3. – p. 283-95. doi: 10.1055/s-2004-829501
Henkle E., Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts // Clin Chest Med. – 2015. – Vol. 36. – N. 1. – p. 91-9. doi: 10.1016/j.ccm.2014.11.002.
Holland S.M. Nontuberculous mycobacteria // Am J Med Sci. – 2001. - Vol. 321. – N 1. – p. 49-55. doi: 10.1097/00000441-200101000-00008.
Huang H.L., Lu P.L., Lee C.H., Chong I.W. Treatment of pulmonary disease caused by Mycobacterium kansasii // J Formos Med Assoc. – 2020. – Vol. 119, Suppl 1. – p. S51-S57. doi: 10.1016/j.jfma.2020.05.018.
Huitric E., Verhasselt P., Koul A., Andries K., Hoffner S., Andersson D. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor // Antimicrob Agents Chemother. – 2010. – Vol. 54. – N3. – p. 1022-8. doi: 10.1128/AAC.01611-09.
Johnston J.C., Chiang L., Elwood K. Mycobacterium kansasii // Microbiol Spectr. – 2017. – Vol. 5. – N.1. - doi: 10.1128/microbiolspec.TNMI7-0011-2016.
Kim D., Jhun B., Moon S., Kim S., Jeon K., Kwon O. et al. In vitro activity of bedaquiline and delamanid against nontuberculous mycobacteria, including macrolide-resistant clinical isolates // Antimicrob Agents Chemother. – 2019. – Vol. 63: e00665-19. doi: 10.1128/AAC. 00665-19.
Koh W. Nontuberculous Mycobacteria-Overview // Microbiol Spectr. – 2017. – Vol. 5. N.1. doi: 10.1128/microbiolspec.TNMI7-0024-2016.
Kumar K., Loebinger M.R. Nontuberculous mycobacterial pulmonary disease: clinical epidemiologic features, risk factors, and diagnosis: the nontuberculous mycobacterial series // Chest. – 2022. – Vol. 161. – N 3. – p. 637-646. doi: 10.1016/j.chest.2021.10.003.
Li Y., Liu C., Ma A., He W.., Qiu Q, Zhao Y., Li Y. Identification and drug susceptibility testing of the subspecies of Mycobacterium avium complex clinical isolates in mainland China // J Glob Antimicrob Resist. – 2022. – Vol. 31. – p. 90-97. doi: 10.1016/j.jgar.2022.05.027.
Litvinov V., Makarova M., Galkina K., Khachaturiants E., Krasnova M., Guntupova L., Safonova S. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system // PLoS One. – 2018. – Vol. 13. – N. 9:e0203108. doi: 10.1371/journal.pone.0203108.
Litvinov V., Makarova M., Kudlay D., Nikolenko N., Mikhailova J. Invitro activity of bedaquiline against Mycobacterium avium complex // J ed Microbiol. – 2021. – Vol. 70. – N10. doi: 10.1099/jmm.0.001439.
Martin A., Godino I., Aguilar-Ayala D., Mathys V., Lounis N., Villaobos H. In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria // J Med Microbiol. – 2019. – Vol. 68. – N 8. – p. 1137-1139. doi: 10.1099/jmm. 0.001025.
Mirzayev F., Viney K., Linh N., Gonzalez-Angulo L., Gegia M., Jaramillo E., Zignol M., Kasaeva T. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update // Eur Respir J. – 2021. – Vol.7. – N.6:2003300. doi: 10.1183/13993003.03300-2020.
Pang Y., Zheng H., Tan Y., Song Y., Zhao Y. In vitro activity of bedaquiline against nontuberculous mycobacteria in China // Antimicrob Agents Chemother 2007. – Vol. 61: e02627-16. doi: 10.1128/AAC.02627-16.
Pennington K.M., Vu A., Challener D., Rivera C.G., Shweta F.N.U., Zeuli J.D., Temesgen Z. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Other Mycobact Dis. – 2021. – Vol. 24:100244. doi: 10.1016/j.jctube.2021.100244.
Philley J., Griffith D. Medical Management of Pulmonary Non-tuberculous Mycobacterial Disease // Thorac Surg Clin. – 2019. – Vol. 29. – p. 65-76. doi: 10.1016/j.thorsurg.2018.09.001.
Prevots D., Marras T. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review // Clin Chest Med. – 2015. – Vol. 36. - №1. – р 13-34. doi: 10.1016/j.ccm.2014.10.002.
Ruth M., Sangen J., Remmers K., Pennings L., Svensson E., Aarnoutse R. et al. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria // J Antimicrob Chemother. – 2019. – Vol. 74. – р. 35-943. doi: 10.1093/jac/dky526.
Sharma S.K., Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases // Indian J Med Res. – 2020. – Vol 152. – №3. – р. 185-226. doi: 10.4103/ijmr.IJMR_902_20.
Shinohara T, Morizumi S, Sumitomo K. Varying clinical presentations of nontuberculous mycobacterial disease: Similar to but different from tuberculosis // J Med Invest. – 2021. – Vol. 68. – N 3-4. – р. 220-227. doi: 10.2152/jmi.68.220.
Thomson R. M. Сhanging epidemiology of pulmonary nontuberculous mycobacteria infections // Emerg. Infect. Dis. – 2010. – Vol. 16 (10). – p. 1576-1583.
To K, Cao R, Yegiazaryan A, Owens J, Venketaraman V. General Overview of Nontuberculous Mycobacteria Opportunistic Pathogens: Mycobacterium avium and Mycobacterium abscessus // J Clin Med. – 2020. – Vol. 9 (№ 6). doi: 10.3390/jcm9082541.
Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections // Clin Microbiol Infect. – 2009. – Vol. 15. – N1. – p. 6-10.
Turenne C.Y. Nontuberculous mycobacteria: Insights on taxonomy and evolution // Infect Genet Evol. – 2019. – Vol. 72. – p. 159-168. doi: 10.1016/j.meegid.2019.01.017.
van Ingen J., Boeree M., van Soolingen D., Mouton J. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria // Drug Resist Updat. – 2012. – Vol. 15. № 3. – р. 149-61. doi: 10.1016/j.drup.2012.04.001.
van Ingen J., Kuijper E. Drug susceptibility testing of nontuberculous mycobacteria // Future Microbiol. – 2014. – Vol. 9. – p. 1095-110. doi: 10.2217/fmb.14.60.
van Ingen J., Obradovic M., Hassan M., Lesher B., Hart E., Chatterjee A., Daley C. L. Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments. Expert Rev Respir Med. – 2021. – Vol. 15. – № 11. – p. 1387-1401. doi: 10.1080/17476348.2021.1987891. Epub 2021 Oct 18. PMID: 34612115.
Varley C.D., Winthrop K.L. Nontuberculous Mycobacteria: Diagnosis and Therapy// Clin Chest Med. – 2022. – Vol. 43. – N 1. – p. 89-98. doi: 10.1016/j.ccm.2021.11.007.
Venugopal D., Kumar S., Isa M., Bose M. Drug resistance profile of human Mycobacterium avium complex strains from Indna // Indian. J. Med. Microbiol. – 2007. – Vol. 25, N 2. – pp. 115-20.
Vesenbeckh S., Schönfeld N., Krieger D., Bettermann G., Bauer T., Rüssmann H. et al. Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections // Eur Respir J. – 2017. – Vol. 49. – N 3 – 1601969. doi: 10.1183/13993003.01969-2016.
Vesenbeckh S., Schönfeld N., Roth A., et al. Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections // Eur Respir J. – 2017. – Vol. 49. – N 5. – p. 1700083. doi: 10.1183/13993003.00083-2017. 3131
Wetzstein N., Geil A., Kann G. et al. Disseminated disease due to non-tuberculous mycobacteria in HIV positive patients: A retrospective case control study. PLoS One. – 2021. – Vol. 16. – N 7. – e0254607. doi: 10.1371/journal.pone.0254607.
WHO. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva: World Health Organization; 2013.
Winthrop K., McNelley E., Kendall B. et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. // Am. J. Respir. Crit. Care Med. – 2010. – v.182. – p. 977-982.
Zweijpfenning S.M.H., Ingen J.V., Hoefsloot W. Geographic distribution of nontuberculous mycobacteria isolated from clinical specimens: a systematic review. Semin Respir Crit Care Med. – 2018. – Vol. 39. – N 3336-342. doi: 10.1055/s-0038-1660864.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница